| Literature DB >> 26184824 |
E M Gielis1,2, K J Ledeganck1, B Y De Winter1, J Del Favero3, J-L Bosmans1,4, F H J Claas2, D Abramowicz1,4, M Eikmans2.
Abstract
After organ transplantation, donor-derived cell-free DNA (ddcfDNA) can be detected in the recipient's blood and urine. Different ddcfDNA quantification techniques have been investigated but a major breakthrough was made with the introduction of digital droplet PCR and massive parallel sequencing creating the opportunity to increase the understanding of ddcfDNA kinetics after transplantation. The observations of increased levels of ddcfDNA during acute rejection and even weeks to months before histologic features of graft rejection point to a possible role of ddcfDNA as an early, noninvasive rejection marker. In this review, we summarize published research on ddcfDNA in the transplantation field thereby elaborating on its clinical utility. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.Entities:
Keywords: biomarker; clinical research/practice; kidney transplantation/nephrology; molecular biology; molecular biology: DNA; organ transplantation in general; rejection: acute; translational research/science
Mesh:
Substances:
Year: 2015 PMID: 26184824 DOI: 10.1111/ajt.13387
Source DB: PubMed Journal: Am J Transplant ISSN: 1600-6135 Impact factor: 8.086